Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Age and sex specific coronary plaque characteristics among South Asians: Insights from the DILWALE CTA study.

American journal of preventive cardiology·2026
Same authorSame journal

Beyond LDL-C: Triangulating residual risk via lipoprotein(a), remnant cholesterol, and vascular inflammation.

Progress in cardiovascular diseases·2026
Same author

Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline.

Current atherosclerosis reports·2026
Same author

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference.

Current atherosclerosis reports·2026
Same author

Diagnostic Performance of Two CCTA Derived Noninvasive FFR Techniques: The TripleFFR Study.

Circulation. Cardiovascular imaging·2026
Same author

Global Burden of Cardiovascular Disease: What Should Be Expected in the Next 25 Years?

Current cardiology reports·2026

関連する実験動画

Updated: Sep 10, 2025

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.1K

心不全に対する細胞治療 - 最近の進展と将来の方向

Roberto Bolli1, Joshua M Hare2, Emerson C Perin3

  • 1Division of Cardiology, University of Louisville, Louisville, KY, United States of America.

Progress in cardiovascular diseases
|August 27, 2025
PubMed
まとめ

細胞治療は心臓機能不全 (HF) の治療に有望であり,メゼンキマ・ストロマ細胞 (MSC) は臨床試験で安全性と潜在的利益を示しています. 効果を確認し,HF治療の有効な選択肢として細胞治療を確立するために,さらなる大規模な研究が必要である.

キーワード:
幹細胞心臓再生心臓の修復心不全

さらに関連する動画

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart
11:45

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart

Published on: January 7, 2019

6.7K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.0K

関連する実験動画

Last Updated: Sep 10, 2025

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.1K
Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart
11:45

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart

Published on: January 7, 2019

6.7K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.0K

科学分野:

  • 再生医療
  • 心臓病科
  • 細胞生物学

背景:

  • 心不全 (HF) の罹患率は世界的に増加しており,公衆衛生上の大きな課題となっています.
  • HFの現在の治療には限界があり,新しい治療戦略が必要である.
  • 細胞治療は,HFのアウトカムを改善する有望なアプローチとして現れた.

研究 の 目的:

  • 心不全の細胞治療の進展と将来の方向性を検討する.
  • HF治療における様々な細胞の安全性と有効性のデータを要約する.
  • 強化されたHF治療のための新しい細胞タイプと配信戦略を探求する.

主な方法:

  • HFの細胞療法に関する既存の文献のレビュー.
  • 数多くの研究とランダム化制御試験からの安全性データの分析.
  • メゼンキマ・ストロマ細胞 (MSC) を用いた臨床試験の結果の評価

主要な成果:

  • 細胞療法,特にMSCは,HF患者で強力な安全性プロファイルを示しています.
  • いくつかの試験は,心筋病の臨床結果に対する細胞治療の有益な効果を示しています.
  • 進行中の試験では,繰り返し投与や静脈内投与などの新しい細胞タイプと投与方法が調査されています.

結論:

  • 細胞治療は 心不全の治療法として 重要な可能性を秘めています
  • 確固たる安全性データと有望な有効性シグナルは,さらなる大規模な臨床試験を正当化します.
  • 新しい細胞タイプと戦略に関する研究が続けられれば,HF管理のための細胞治療を最適化することができます.